Anhydrous pharmaceutical composition for maintenance therapy of psoriasis

By using anhydrous pharmaceutical compositions, including caspotriol, betamethasone dipropionate and propellant, as topical medications for psoriasis, maintenance treatment is achieved twice a week, and the existing treatment methods are solved Side effects and poor maintenance effects significantly improve the safety and effectiveness of treatment.

CN119055590APending Publication Date: 2024-12-03LEO PHARMA AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411210400.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-10-08
Filing Date
2020-10-07
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing treatment methods for psoriasis have side effects, such as skin atrophy, skin striae, acne-like rash, etc., and long-term treatment is difficult to effectively prevent attacks, and the maintenance treatment effect is not good.

Method used

Anhydrous pharmaceutical compositions are employed, comprising about 0.005% w/w of caspotriol or caspotriol monohydrate, about 0.064% w/w of betamethasone dipropionate and vaseline, in combination with pharmaceutically acceptable propellant , as a topical drug, used for twice a week for maintenance treatment of patients with psoriasis.

Benefits of technology

It significantly reduces the number of episodes and the time of first recurrence, increases the number of days without episodes, reduces the accumulated amount of drugs, improves the safety and tolerability of treatment, and reduces the risk of side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005020169000000051
    Figure BDA0005020169000000051
  • Figure BDA0005020169000000091
    Figure BDA0005020169000000091
  • Figure BDA0005020169000000101
    Figure BDA0005020169000000101
Patent Text Reader

Abstract

The present invention relates to an anhydrous topical pharmaceutical composition for the maintenance treatment of psoriasis patients in remission, comprising calcipotriol and betamethasone as active ingredients, vaseline and a propellant.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application 202080072676.5, with an application date of October 7, 2020, a priority date of October 8, 2019, and application publication number CN114555055 A. Technical Field

[0002] Psoriasis vulgaris is a chronic inflammatory disease typically treated with topical interventions that presents a lifelong burden for many patients. Psoriasis is characterized by frequent flare-ups, and there is a clear need for an effective and well-tolerated long-term topical treatment to reduce flare-ups.

[0003] The present invention relates to an anhydrous pharmaceutical composition comprising betamethasone dipropionate and calcipotriol for twice-weekly administration for preventing flare-ups and prolonging the flare-free interval in psoriasis patients who are in remission after treatment for psoriasis. Background Art

[0004] Psoriasis is a chronic inflammatory skin disease characterized by red, dry, scaly plaques caused by hyperkeratosis. These plaques most commonly appear on the elbows, knees, and scalp, although more widespread lesions may occur elsewhere on the body, particularly the lumbar region or scalp. Common treatments for mild to moderate psoriasis involve topical application of compositions containing corticosteroids as active ingredients. While effective, the use of corticosteroids has the disadvantage of numerous side effects, such as skin atrophy, striae, acneiform rashes, perioral dermatitis, fungal and bacterial overgrowth on the skin, hypopigmentation of hyperpigmented skin, and rosacea.

[0005] Psoriasis can also be treated with antibodies such as Adalimumab, Adalimumab-adbm, Brodalumab, Certolizumab pegol, Etanercept, Etanercept-szzs, Guselkumab, Infliximab, Ixekizumab, Risankizumab-rza, Secukinumab, and Ustekinumab, or oral preparations such as those containing Apremilast.

[0006] A topical combination product for the treatment of psoriasis is already available from LEO Pharma under the trade name It is sold as an ointment and a gel. This product contains calcipotriol monohydrate and betamethasone dipropionate as active ingredients formulated in a composition containing polyoxypropylene stearyl ether as a solvent.

[0007] Another combination product for the treatment of psoriasis is marketed by LEO Pharma under the trade name This product contains calcipotriol monohydrate and betamethasone dipropionate as active ingredients formulated in a white petrolatum-based composition containing polyoxypropylene stearyl ether, wherein the active ingredients are dissolved in a propellant.

[0008] It has been found that Compared with ointments and gels, Skin foams deliver more active substances into the skin, resulting in higher efficacy in treating psoriasis, see Lind et al., Dermatol Ther (Heidelb) (2016) 6:413-25 and Queille-Roussel et al., Clin Drug Investig (2015) 35:239-45.

[0009] The skin foam is an effective treatment for psoriasis vulgaris and is approved for once-daily treatment of psoriasis vulgaris for up to four weeks. Overview of product properties of skin foam.

[0010] It has now been surprisingly found that long-term twice-weekly maintenance treatment with this foam composition is safe in psoriasis patients.

[0011] It has also been found that patients in remission treated with this foam composition twice weekly have significantly improved number of relapses, time to first relapse, and days in remission within one year compared to patients in remission not treated with this composition.

[0012] Thus, the present invention relates to a foam composition for maintenance therapy in patients with psoriasis, wherein the composition is administered twice a week while the patient is in remission. Summary of the Invention

[0013] Summary of the Invention

[0014] The present invention provides an anhydrous topical pharmaceutical composition comprising:

[0015] A pharmaceutically acceptable lipid carrier comprising:

[0016] about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate,

[0017] approximately 0.064% w / w betamethasone dipropionate, and

[0018] Vaseline;

[0019] and comprising, in addition to the pharmaceutically acceptable lipid carrier, a pharmaceutically acceptable propellant; for maintenance treatment of a psoriasis patient, wherein the pharmaceutical composition is administered twice weekly while the psoriasis patient is in remission, and wherein an improved treatment outcome is achieved compared to a patient who is not administered the pharmaceutical composition while in remission.

[0020] In a specific embodiment, the present invention relates to an anhydrous topical pharmaceutical composition comprising: a pharmaceutically acceptable lipid carrier comprising:

[0021] about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate,

[0022] approximately 0.064% w / w betamethasone dipropionate, and

[0023] Vaseline;

[0024] and comprising, in addition to the pharmaceutically acceptable lipid carrier, a pharmaceutically acceptable propellant; for maintenance treatment of a psoriasis patient, wherein (i) when the psoriasis patient is in remission after treating a flare with the composition once daily for up to 4 weeks, the pharmaceutical composition is administered twice a week, and (ii) when a flare occurs, administration of the composition is resumed once a day for up to 4 weeks,

[0025] wherein an improved therapeutic outcome is achieved compared to patients in remission who are not administered the pharmaceutical composition.

[0026] According to the present invention, improved treatment results are achieved using lower cumulative amounts of the pharmaceutical composition compared to patients who administer the pharmaceutical composition only when the patient experiences a psoriasis flare-up.

[0027] According to one embodiment of the present invention, the improved treatment outcome is a reduction in the number / rate of attacks by up to 37-54%.

[0028] According to one embodiment of the present invention, the improved treatment outcome is an 80-90% increase in the number of days until first relapse.

[0029] According to one embodiment of the present invention, the improved treatment outcome is 5-15% more days of remission per year.

[0030] According to one embodiment of the present invention, the improved treatment outcome is a reduction in the number of attacks by up to 46%.

[0031] According to one embodiment of the present invention, the improved treatment outcome is an 87% increase in the number of days until first relapse.

[0032] According to one embodiment of the present invention, the improved treatment outcome is 11% more days of remission per year. Detailed Description of the Invention

[0034] In a Phase 3 randomized double-blind trial, the efficacy and safety of Composition G as described herein were compared with placebo for twice-weekly maintenance treatment of psoriasis patients in remission, showing the following benefits:

[0035] The median time to first relapse was 56 days for Composition G and 30 days for vehicle, respectively.

[0036] Composition G reduced the risk of first relapse by 43% compared with vehicle (HR, 0.57; 95% CI, 0.47-0.69; P<0.0001).

[0037] The one-year relapse rate was reduced by 46% in the Composition G group compared with vehicle (95% CI, 37-54%; P<0.001); the mean number of expected relapses within one year was 4.0 for Composition G and 7.5 for vehicle, respectively.

[0038] Patients in the Composition G group experienced 11% more days of remission than those in the vehicle group (P<0.0001). Over one year, this equated to 41 additional days of remission (95% CI, 29-51 days).

[0039] Composition G was well tolerated over the 52-week study period. The incidence of rebound was lower in the Composition G group than in the vehicle group. No new striae, skin atrophy, or clinically significant HPA axis suppression cases were reported in either treatment group.

[0040] Thus, the present invention relates to the treatment of patients who are in remission after treatment with one or more active substances or compositions known to be effective in treating psoriasis. The active substances or compositions may be any known active substances or compositions useful in treating psoriasis, for example Gel or ointment, Daivonex cream or ointment, topical products containing corticosteroids or other topical products, antibodies such as adalimumab, adalimumab-adbm, brodalumab, certolizumab pegol, etanercept, etanercept-szzs, guselkumab, infliximab, isilakinumab, risankizumab, secukinumab, and ustekinumab, or oral preparations, such as those containing apremilast.

[0041] The composition used according to the present invention comprises a pharmaceutically acceptable lipid carrier comprising

[0042] about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate,

[0043] About 0.064% w / w betamethasone dipropionate,

[0044] and Vaseline;

[0045] In addition to the pharmaceutically acceptable lipid carrier, the composition further comprises a pharmaceutically acceptable propellant.

[0046] Whenever "the composition" is referred to herein, the term refers to a composition comprising a pharmaceutically acceptable lipid carrier comprising

[0047] about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate,

[0048] About 0.064% w / w betamethasone dipropionate,

[0049] and Vaseline;

[0050] In addition to the pharmaceutically acceptable lipid carrier, the composition further comprises a pharmaceutically acceptable propellant.

[0051] The term "about" as used in the context of an amount expressed as % w / w means plus / minus 10% of that amount.

[0052] As used herein, an anhydrous pharmaceutical composition is a composition to which water has not been added as an excipient or pharmaceutical inactive ingredient. The inactive ingredients added to the composition may contain small amounts of water as impurities, but no inactive ingredient contains any significant amount of water, e.g., more than 1% water.

[0053] Psoriasis is a chronic disease, and people with psoriasis experience multiple flare-ups each year.

[0054] As used herein, a patient in remission refers to an individual who has achieved treatment success following treatment with a medication that is effective for treating psoriasis.

[0055] A flare means an increase in psoriasis symptoms, for example to a level defined as at least "mild" PGA.) As used herein, flare and relapse have the same meaning.

[0056] PGA stands for Physicians Global Assessment (PGA), a widely recognized measure of psoriasis symptoms that EMEA requires pharmaceutical companies to use in clinical trials. PGA is assessed according to Table 1 below.

[0057] Table 1: Disease severity classification—physician assessment

[0058]

[0059] Maintenance therapy refers to long-term treatment to prevent attacks and prolong the attack-free period. As used herein, maintenance therapy, long-term maintenance therapy and active management have the same meaning.

[0060] As used herein, twice weekly means administration twice a week with an interval of 2 to 3 days between administrations.

[0061] The pharmaceutically acceptable lipid vehicle used according to the present invention comprises the active ingredients calcipotriol and betamethasone and petrolatum.

[0062] Vaseline, white petrolatum or white soft paraffin are commonly used lipid carriers, which are composed of different chain lengths with a peak of about C 40-44 White soft paraffin or white petrolatum can seal the treated skin surface, reduce transepidermal water loss and enhance the therapeutic effect of the active ingredients in the composition. It tends to have a greasy or sticky feel that lasts for a considerable period of time after application.

[0063] Liquid paraffin can be added to petroleum jelly to make it softer. Liquid paraffin consists of different chain lengths, peaks of C 28-40 of hydrocarbon composition.

[0064] It is preferred to use paraffin wax composed of hydrocarbons with a slightly lower chain length, for example, a hydrocarbon with a peak chain length of C 14-16 、C 18-22 、C 20-22 、C 20-26 The paraffin wax of hydrocarbon or its mixture composition. It has been found that this type of paraffin wax is more acceptable in cosmetics because they are not so greasy or sticky when applied. Therefore, it is expected that including this type of paraffin wax in the composition of the present invention can cause patient compliance to improve. Suitable paraffin waxes of this type, which are called vaseline jelly (petrolatum jelly), are manufactured by Sonneborn and sold under the brand name Sonnecone, such as Sonnecone CM, Sonnecone DM1, Sonnecone DM2 and Sonnecone HV. These paraffin waxes are further disclosed and characterized in WO2008 / 141078, which is incorporated herein by reference. In addition to their favorable cosmetic properties, it has also been surprisingly found that compositions containing these paraffin waxes as carriers are more easily tolerated than compositions containing conventional paraffin waxes. (The hydrocarbon composition of the paraffin wax has been determined by gas chromatography).

[0065] The lipid vehicle usually comprises petrolatum, particularly white petrolatum or white soft paraffin, as the major component by weight, and contains liquid paraffin to soften the petrolatum.

[0066] Suitably, the lipid vehicle comprises more than 80% w / w petrolatum, more than 85% w / w petrolatum or more than 90% w / w petrolatum, suitably white soft paraffin or white petrolatum.

[0067] The compositions used according to the invention may contain an antioxidant, such as alpha-tocopherol or butylated hydroxytoluene.

[0068] The pharmaceutically acceptable propellant may be selected from dimethyl ether, methyl ethyl ether or C 3-5 Alkanes, halogenated C 3-5 Olefins. Suitable C 3-5 The alkane is propane, n-butane, isobutane or propane, pentane or a mixture thereof. Suitable halogenated C 3-5 The olefin was HFO-1234ze(E) (trans-1,3,3,3-tetrafluoroprop-1-ene).

[0069] In some embodiments, calcipotriol, calcipotriol monohydrate, and / or betamethasone dipropionate are dissolved in the propellant.

[0070] According to one embodiment of the present invention, the pharmaceutically acceptable propellant comprises C 3-5 Alkanes or halogenated C 3-5 Olefins, such as n-butane.

[0071] In a particular embodiment of the present invention, the pharmaceutically acceptable propellant comprises dimethyl ether.

[0072] In another embodiment of the present invention, the pharmaceutically acceptable propellant is present in the composition in an amount sufficient to completely dissolve the calcipotriol or calcipotriol monohydrate and betamethasone dipropionate.

[0073] According to one such embodiment of the invention, the pharmaceutically acceptable propellant comprises dimethyl ether, and the calcipotriol or calcipotriol monohydrate and betamethasone dipropionate are dissolved in the dimethyl ether.

[0074] According to another such embodiment, the pharmaceutically acceptable propellant comprises dimethyl ether, and calcipotriol or calcipotriol monohydrate and betamethasone dipropionate are dissolved in a mixture of dimethyl ether and a second propellant. The second propellant is suitably C 3-5 Alkanes or halogenated C 3-5 Olefins, such as n-butane.

[0075] Suitably, C 3-5 Alkanes or halogenated C 3-5 The ratio of olefin to dimethyl ether ranges from about 6:1 to 0.5:1 w / w, about 5:1 to 1:2 w / w, about 4:1 to 1:1 w / w, about 4:2 to 1:1 w / w, 4:2 to 4:3 w / w, or 4:3 to 1:1 w / w.

[0076] The lipid carrier in the formulation used according to the present invention is dissolved or suspended in the propellant.

[0077] The pharmaceutically acceptable lipid carrier may contain an oily cosolvent. The cosolvent may be selected from:

[0078] (a) General Formula I: H(OCH2C(CH3)H) x OR1 A compound wherein R 1 Is a straight chain or branched C 1-20 alkyl, and x is an integer from 2 to 60, inclusive;

[0079] (b) Straight or branched chain C 10-18 Isopropyl esters of alkanoic or alkenoic acids;

[0080] (c)C 8-14 Propylene glycol diesters of alkanoic or alkenoic acids;

[0081] (d) Straight or branched chain C 8-24 Alkanol or alkenol;

[0082] (e) vegetable oils; and

[0083] (f) N-alkylpyrrolidone or N-alkylpiperidone.

[0084] In one embodiment, the pharmaceutically acceptable cosolvent is polyoxypropylene-15-stearyl ether, polyoxypropylene-11-stearyl ether, polyoxypropylene-14-butyl ether, polyoxypropylene-10-cetyl ether, or polyoxypropylene-3-myristyl ether.

[0085] In one embodiment, the pharmaceutically acceptable co-solvent is isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isopropyl linolate, or isopropyl monooleate.

[0086] In one embodiment, the pharmaceutically acceptable co-solvent is propylene glycol dipelargonate.

[0087] In one embodiment, the pharmaceutically acceptable cosolvent is octanol, lauryl alcohol, cetyl alcohol, stearyl alcohol or myristyl alcohol. 8-24 Alkenyl alcohol is oleyl alcohol or linoleyl alcohol, or branched C 8-24 Alkanol is a branched C 18-24 Alkanol.

[0088] In one embodiment, the pharmaceutically acceptable co-solvent is myristyl alcohol or oleyl alcohol.

[0089] In one embodiment, the pharmaceutically acceptable co-solvent is N-methylpyrrolidone.

[0090] In one embodiment, the pharmaceutically acceptable co-solvent is a refined vegetable oil, such as refined coconut oil or medium chain triglycerides.

[0091] In one embodiment, the pharmaceutically acceptable co-solvent is polyoxypropylene-11-stearyl ether.

[0092] The amount of co-solvent used depends on the ability of the co-solvent to dissolve the active ingredient, but generally ranges from 0.5-25% w / w, 0.5-10% w / w, 1-5% w / w or 3-5% w / w of the pharmaceutically acceptable lipid carrier. The amount of co-solvent is suitably less than that sufficient to dissolve the active substance in the formulation.

[0093] In one embodiment, the propellant is present in an amount to completely dissolve the active agent, and the amount of co-solvent is less than an amount sufficient to dissolve the active agent in the lipid vehicle.

[0094] The topical compositions for use according to the present invention are applied dermally or transdermally. The composition is sprayed onto the area of ​​skin affected by a psoriasis flare-up and then rubbed in with the hands.

[0095] The composition for use according to the present invention may be prepared as described in WO2011154004 or by analogous methods. WO2011154004 is incorporated herein by reference.

[0096] Implementation plan:

[0097] Embodiment 1: A method for maintaining treatment of a psoriasis patient in remission, wherein the method comprises treating the patient twice weekly with a pharmaceutical composition comprising:

[0098] A pharmaceutically acceptable lipid carrier comprising:

[0099] about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate,

[0100] About 0.064% w / w betamethasone dipropionate,

[0101] and Vaseline, and

[0102] and comprising, in addition to the pharmaceutically acceptable lipid carrier, a pharmaceutically acceptable propellant;

[0103] wherein an improved therapeutic outcome is achieved compared to patients in remission who are not administered the pharmaceutical composition.

[0104] Embodiment 2: A method for maintenance treatment of a psoriasis patient in remission following once daily treatment of a flare for up to 4 weeks with an anhydrous pharmaceutical composition comprising:

[0105] A pharmaceutically acceptable lipid carrier comprising:

[0106] about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate,

[0107] About 0.064% w / w betamethasone dipropionate,

[0108] and Vaseline, and

[0109] and comprising, in addition to the pharmaceutically acceptable lipid carrier, a pharmaceutically acceptable propellant;

[0110] wherein the method comprises treating the patient with the pharmaceutical composition twice weekly, and wherein an improved treatment outcome is achieved using a lower amount of the pharmaceutical composition compared to a patient in remission who is not administered the pharmaceutical composition.

[0111] Embodiment 3: Use of betamethasone dipropionate and calcipotriol or calcipotriol monohydrate in the preparation of an anhydrous pharmaceutical composition, the anhydrous pharmaceutical composition comprising:

[0112] A pharmaceutically acceptable lipid carrier comprising

[0113] about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate,

[0114] About 0.064% w / w betamethasone dipropionate,

[0115] and Vaseline, and

[0116] and comprising, in addition to the pharmaceutically acceptable lipid carrier, a pharmaceutically acceptable propellant;

[0117] For use in the maintenance treatment of psoriasis patients in remission, wherein the anhydrous pharmaceutical composition is administered to the patient twice weekly, and wherein an improved treatment outcome is achieved compared to patients in remission who are not administered the pharmaceutical composition.

[0118] Embodiment 4: Use of betamethasone dipropionate and calcipotriol or calcipotriol monohydrate in the preparation of a pharmaceutical composition for the maintenance treatment of a psoriasis patient in remission after a flare-up has been treated once daily with an anhydrous pharmaceutical composition for up to 4 weeks, the anhydrous pharmaceutical composition comprising: a pharmaceutically acceptable lipid carrier comprising

[0119] about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate,

[0120] About 0.064% w / w betamethasone dipropionate,

[0121] and Vaseline, and

[0122] and comprising, in addition to the lipid carrier, a pharmaceutically acceptable propellant;

[0123] wherein the pharmaceutical composition is administered to the patient twice weekly, and wherein an improved therapeutic outcome is achieved using a lower amount of the composition compared to a patient who is not administered the pharmaceutical composition in remission. DETAILED DESCRIPTION

[0124] Example 1

[0125] Compositions A to E and G

[0126] To prepare compositions A to E and G, white soft paraffin was melted at 80°C, then cooled to 70°C and maintained at that temperature. Calcipotriol monohydrate was dissolved in polyoxypropylene-15-stearyl ether to form a solution, which was added to the molten paraffin with stirring. BDP was dispersed in liquid paraffin, and the dispersion was added to the paraffin mixture containing calcipotriol with stirring, and the mixture was then cooled to below 30°C. A 30g portion of the mixture was transferred to an aluminum spray container equipped with a polyamide-polyimide inner lacquer (HOBA 8460), and the valve cup was then secured to the container body by crimping. The required amount of propellant mixture was added via tube, and the container was then shaken for 5 minutes to completely dissolve the calcipotriol and BDP.

[0127] Composition A

[0128]

[0129]

[0130] Composition B

[0131]

[0132] Composition C

[0133]

[0134] Composition D

[0135]

[0136]

[0137] Composition E

[0138]

[0139] Composition F

[0140] To prepare composition F, hydrogenated castor oil was melted together with liquid paraffin at 85-90°C and cooled to about 60°C by homogenization. The mixture was then cooled to 25-30°C with stirring. BDP was suspended in liquid paraffin and added to the homogenized mixture. Calcipotriol monohydrate was dissolved in polypropylene-15-stearyl ether and added to the mixture of the other ingredients, and the preparation was homogenized to ensure uniform distribution of the active ingredient. A 30 g portion of the mixture was transferred to an aluminum spray container equipped with a polyamide-polyimide inner lacquer (HOBA 8460), and the valve cup was then fixed to the container body by crimping. The required amount of propellant mixture was added via a tube, and the container was then shaken for 5 minutes to completely dissolve the calcipotriol and BDP.

[0141] Composition F

[0142]

[0143]

[0144] Composition G

[0145]

[0146] (*)PPG-1-stearyl ether contains butylated hydroxytoluene as an antioxidant.

[0147] Composition H to N

[0148] To prepare compositions H to N, white soft paraffin and α-tocopherol were mixed by heating to about 80°C with stirring. The mixture was cooled to about 60°C. Micronized calcipotriol hydrate and BDP were dispersed in liquid paraffin and added to the molten paraffin with stirring. The mixture was then cooled to below 30°C with stirring. A 30 g portion of the mixture was transferred to an aluminum spray container equipped with a polyamide-polyimide inner lacquer (HOBA 8460), and the valve cup was secured to the container body by crimping. The required amount of propellant mixture was added via tube, and the container was then shaken for 5 minutes to completely dissolve the calcipotriol and BDP.

[0149] To prepare composition SW, white soft paraffin and α-tocopherol were mixed by heating to approximately 80°C with stirring. The mixture was cooled to approximately 70°C. Calcipotriol monohydrate was dissolved in the co-solvents medium-chain triglycerides, oleyl alcohol, and isopropyl myristate, respectively, by heating to approximately 60°C to form a solution, which was then added to the molten paraffin α-tocopherol mixture with stirring. The mixture was then cooled to approximately 60°C and maintained at this temperature. BDP was dispersed in liquid paraffin, and the dispersion was added to the paraffin mixture containing calcipotriol with stirring, after which the mixture was cooled to below 30°C with stirring. A 30g portion of the mixture was transferred to an aluminum spray container equipped with a polyamide-polyimide inner lacquer (HOBA 8460), and the valve cup was secured to the container body by crimping. The required amount of the propellant mixture was added via a tube, and the container was shaken for 5 minutes to completely dissolve the calcipotriol and BDP.

[0150]

[0151] Table 2: Formulations without propellant weight contribution HN contains 0.005% w / w calcipotriol, 0.064% w / w betamethasone dipropionate.

[0152] Example 2

[0153] Clinical testing of efficacy

[0154] Composition G of Example 1 was tested in a Phase III, multicenter, randomized, vehicle-controlled trial consisting of an open-label active treatment period (4 weeks), a randomized double-blind active management period (52 weeks), and an eight-week follow-up period.

[0155] After the screening period, subjects deemed eligible for the trial (adults with psoriasis vulgaris rated as at least "mild" on the trunk and / or limbs according to PGA, BSA 2-30% and m-PASI at least 2) were enrolled in an initial open-label period in which they applied Composition G once daily to the psoriasis lesions on the trunk and / or limbs for up to 4 weeks.

[0156] Subjects who achieved treatment success (PGA score of "clear" or "almost clear," at least a 2-grade improvement from baseline) at Week 4 were randomized in a 1:1 ratio to a 52-week maintenance period of twice-weekly Composition G or vehicle (Maintenance IP).

[0157] - Subjects who did not achieve treatment success after once-daily treatment for up to 4 weeks (ie, non-responders) were discontinued from the trial.

[0158] During the randomized maintenance phase, subjects applied maintenance IP twice weekly every 3 or 4 days (fixed days) on all areas of the trunk and limbs where lesions had cleared or nearly cleared after the initial open-label period or relapse treatment. Subjects were assessed regularly (up to every 4 weeks) during clinical visits. In addition, if a subject believed that a relapse (exacerbation of psoriasis) had occurred between two regularly scheduled monthly visits, the subject was assessed by the investigator during an unscheduled visit.

[0159] After confirmation of relapse, subjects were given Composition G and instructed to apply it to active areas of the trunk and / or limbs, regardless of whether these areas were active at baseline or had new lesions. Composition G was applied once daily to the active areas for up to 4 weeks. If other areas became active during rescue treatment, these areas were treated with Composition G once daily. During relapse, inactive areas continued with maintenance treatment twice weekly.

[0160] If a "clear" / "almost clear" score according to the PGA is achieved after up to 4 weeks, the twice-weekly maintenance regimen is restarted in the area that is now "clear" / "almost clear" according to the randomized schedule.

[0161] If a "clear" / "almost clear" score according to the PGA was not achieved after once-daily administration of Composition G for up to 4 weeks, the subject was removed from the trial.

[0162] Inclusion criteria: ≥18 years of age; psoriasis vulgaris on the trunk and / or limbs, involving 2-30% of the body surface area; PGA at least "mild" at the first visit, with a modified Psoriasis Area and Severity Index score ≥2.

[0163] The primary endpoint was time to first relapse (PGA at least "mild"). Secondary endpoints were the number of relapses and the proportion of days in remission (PGA "clear" or "almost clear") during the active management period. Safety, including steroid-related adverse events such as striae, skin atrophy, and hypothalamic pituitary adrenal (HPA) axis suppression (HPA axis testing was performed in a subgroup of patients at weeks 0, 4, 28, and 56), was also assessed (full results are reported separately).

[0164] For each subject, the weight of medication used at each visit interval was determined by calculating the difference between the weight of a full set of canisters dispensed and the weight of the canisters returned.

[0165] result

[0166] A total of 545 patients were randomized to receive Composition G or vehicle, of whom 521 achieved treatment success during the open-label period, including the complete analysis cohort (Composition G, n=256; vehicle, n=265). 251 of the 545 randomized patients (46.1%) completed the study. Disease characteristics at randomization were similar between treatment groups. 82% of randomized patients had a PGA score of "moderate" at baseline.

[0167] The median time to first relapse was 56 days for Composition G and 30 days for vehicle, respectively.

[0168] Composition G reduced the risk of first relapse by 43% compared with vehicle (HR, 0.57; 95% CI, 0.47-0.69; P<0.0001).

[0169] The one-year relapse rate was reduced by 46% in the Composition G group compared with vehicle (95% CI, 37-54%; P<0.001); the mean number of expected relapses within one year was 4.0 for Composition G and 7.5 for vehicle, respectively.

[0170] Patients in the Composition G group experienced 11% more days of remission than those in the vehicle group (P < 0.0001). Over one year, this equated to 41 additional days of remission (95% CI, 29-51 days). Composition G was well tolerated over the 52-week study period. The rebound rate was lower in the Composition G group than in the vehicle group. No new cases of striae, skin atrophy, or clinically significant HPA axis suppression were reported in either treatment group.

[0171] In adults with psoriasis vulgaris, long-term active management with Composition G over 52 weeks was superior to vehicle in prolonging time to first relapse, reducing the number of relapses, and increasing days of remission.

[0172] Furthermore, patients treated twice weekly between relapses used 6% less weight of Composition G, measured in grams of drug per day, over the 52-week treatment period.

[0173] Example 3

[0174] Clinical trial safety

[0175] Patients who achieved treatment success (Physician's Global Assessment of Disease Severity [PGA] score of "clear" / "almost clear," with a ≥2-grade improvement from baseline) after once-daily Composition G for up to 4 weeks were randomly assigned in a 1:1 ratio to receive Composition G or vehicle twice weekly for up to 52 weeks. Inclusion criteria included: age ≥18 years; PGA of at least "mild" on the trunk and / or extremities; involving 2-30% of body surface area (BSA); and a modified Psoriasis Area and Severity Index score (mPASI) ≥2. Additional criteria for the HPA axis subgroup included: PGA of at least "moderate" on the trunk and / or extremities; involving 10–30% of BSA; and normal HPA axis function.

[0176] 545 patients were randomly assigned to Composition G (n=272) or vehicle (n=273). The randomization characteristics were similar between the groups. The incidence of AEs per 100 patient years was 165.1 and 156.1 for the Composition G and vehicle groups, respectively. The incidence of serious AEs per 100 patient years was low and comparable (8.2, Composition G; 7.8, vehicle), as was the incidence of treatment-related AEs (2.7, Composition G; 4.5, vehicle). Two AEs (chorioretinopathy and skin pain) were judged to be related to long-term use of corticosteroids. Three patients (2 Composition G [0.7%]; 1 vehicle [0.4%]) experienced AEs that led to discontinuation. Rebound within two months of entering the active management period occurred in 6 and 7 patients for Composition G and vehicle, respectively. After relapse, rebound with vehicle (n=17) was four times more likely than with Composition G (n=4). Subgroup analyses did not reveal clinically relevant effects on calcium metabolism or the HPA axis.

[0177] HRQoL (health-related quality of life) was assessed using the EuroQol-5D Psoriasis (EQ-5D-5L-PSO) instrument (0-1; 0 = worst health state, 1 = best health state) and the Dermatology Life Quality Index (DLQI) (0-30; 0 = no impairment in quality of life, 30 = maximum impairment). Patient-perceived symptom severity was assessed using the Psoriasis Symptom Inventory (PSI) (0-32; 0 = no severity, 32 = high severity).

[0178] During the open-label period, statistically and clinically significant improvements were observed in all PRO (Proprietary Reported Outcome) measures for flare treatment. Specifically, the mean differences (standard deviation [SD]) from baseline to week 4 were -8.97 (6.18) for PSI scores, -6.02 (5.46) for DLQI scores, and 0.11 (0.15) for EQ-5D scores. Across the three PRO assessment tools, both the active and reactive management groups maintained PRO improvements over the subsequent 52 weeks of randomized treatment. Following initial improvements during the 4-week flare treatment period, patients receiving reactive management had statistically significantly higher mean area under the curve (AUC) scores for both DLQI (15% [p = 0.007]) and PSI (Psoriasis Symptom Inventory) (15% [p = 0.0128]) compared to patients receiving active management during the maintenance period. Additionally, patients who received reactive management also had lower mean EQ-5D AUC scores (1% [p=0.0842]) compared to those who received active management during the maintenance period.

[0179] Table 1: Changes in PSI, DLQI, and EQ-5D Scores from Baseline to Week 4 in Episode Treatment

[0180]

[0181] Table 2: Differences in mean PSI, DLQI, and EQ-5D AUC scores between the active and responder groups and during the maintenance period

[0182] initiative Reactivity difference Statistical significance PSI 4.99 5.74 -0.75 P=0.0128 DLQI 2.95 3.40 -0.45 P=0.007 EQ-5D 0.89 0.88 0.01 P=0.0842

Claims

1. An anhydrous topical pharmaceutical composition comprising A pharmaceutically acceptable lipid carrier comprising: about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate, about 0.064% w / w betamethasone dipropionate, and Vaseline; and comprising, in addition to the pharmaceutically acceptable lipid carrier, a pharmaceutically acceptable propellant; For the maintenance treatment of patients with psoriasis. wherein the pharmaceutical composition is administered twice weekly when the psoriasis patient is in remission, and wherein an improved treatment outcome is achieved compared to patients who are not administered the pharmaceutical composition while in remission.

2. The composition according to claim 1, comprising A pharmaceutically acceptable lipid carrier comprising: about 0.005% w / w calcipotriol or about 0.00522% w / w calcipotriol monohydrate, about 0.064% w / w betamethasone dipropionate, and Vaseline; and comprising, in addition to the pharmaceutically acceptable lipid carrier, a pharmaceutically acceptable propellant; For the maintenance treatment of patients with psoriasis. in (i) administering the pharmaceutical composition twice a week when a psoriasis patient is in remission after treating an attack with the composition once a day for up to 4 weeks, and (ii) when an attack occurs, resuming once daily administration of the composition for up to 4 weeks, wherein an improved treatment outcome is achieved compared to patients in remission who are not administered the pharmaceutical composition.

3. The composition of claim 2, wherein improved treatment outcomes are achieved using a lower amount by weight of the pharmaceutical composition compared to patients who are not administered the pharmaceutical composition in remission.

4. The composition according to any one of claims 1 to 3, wherein the improved therapeutic outcome is a reduction in the number of attacks y by up to 37-54%.

5. The composition according to any one of claims 1 to 4, wherein the improved treatment outcome is an increase of 80-90% in the number of days until relapse.

6. The composition according to any one of claims 1 to 4, wherein the improved treatment outcome is 5-15% more days of remission.

7. The composition of any one of claims 1-6, wherein the lipid carrier comprises more than 80% w / w petrolatum, more than 85% w / w petrolatum, or more than 90% w / w petrolatum.

8. The composition according to any one of claims 1 to 7, wherein the petrolatum is white petrolatum or white soft paraffin.

9. The composition of claim 8, wherein the pharmaceutically acceptable lipid carrier further comprises liquid paraffin.

10. The composition according to any one of claims 1 to 9, wherein the composition further comprises an oily co-solvent.

11. The composition of claim 9, wherein the oily co-solvent comprises at least one of: (a) General formula I: H(OCH2C(CH3)H) x OR 1 A compound wherein R 1 Is it a straight chain or branched chain C 1-20 alkyl, and x is an integer from 2 to 60, inclusive; (b) Straight or branched chain C 10-18 Isopropyl esters of alkanoic or alkenoic acids; (c)C 8-14 Propylene glycol diesters of alkanoic or alkenoic acids; (d) Straight or branched chain C 8-24 Alkanol or alkenol; (e) vegetable oils; and (f) N-alkylpyrrolidone or N-alkylpiperidone.

12. The composition according to claim 11, wherein the compound of formula I is polyoxypropylene-15-stearyl ether, polyoxypropylene-11-stearyl ether, polyoxypropylene-14-butyl ether, polyoxypropylene-10-cetyl ether or polyoxypropylene-3-myristyl ether.

13. The composition of claim 11, wherein the linear or branched C 10-18 The isopropyl ester of alkanoic acid or alkenoic acid is isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isopropyl linoleate or isopropyl monooleate.

14. The composition according to claim 11, wherein the linear C 8-24 The alkanol is octanol, lauryl alcohol, cetyl alcohol, stearyl alcohol or myristyl alcohol, and the C 8-24 Alkenyl alcohol is oleyl alcohol or linoleyl alcohol, or a branched C 8-24 Alkanol is a branched chain C 18-24 Alkanol.

15. The composition according to claim 11, wherein the C 8-24 The alkanol or alkenol is myristyl alcohol or oleyl alcohol.

16. The composition of claim 11, wherein the N-alkylpyrrolidone is N-methylpyrrolidone.

17. The composition of claim 11, wherein the vegetable oil is a medium chain triglyceride.

18. The composition of claim 12, wherein the oily co-solvent comprises polyoxypropylene-11-stearyl ether.

19. A composition according to any one of claims 1 to 18, wherein the propellant is 30-80% w / w, 40-70% w / w or 55-65% w / w of the total composition.

20. The composition according to any one of claims 1 to 19, wherein the pharmaceutically acceptable propellant comprises C 3-5 Chain alkanes.

21. The composition of any one of claims 1 to 19, wherein the pharmaceutically acceptable propellant is present in an amount sufficient to dissolve calcipotriol or calcipotriol monohydrate and / or betamethasone dipropionate.

22. The composition of any one of claims 1-21, wherein the pharmaceutically acceptable propellant comprises dimethyl ether.

23. The composition of claim 22, wherein the pharmaceutically acceptable propellant comprises dimethyl ether and calcipotriol or calcipotriol monohydrate and / or betamethasone dipropionate are dissolved in dimethyl ether.

24. The composition of claim 22, wherein the pharmaceutically acceptable propellant comprises dimethyl ether and a second propellant, and the calcipotriol or calcipotriol monohydrate and / or betamethasone dipropionate are dissolved in the mixture of dimethyl ether and the second propellant.

25. The composition of claim 24, wherein the second propellant comprises C 3-5 Alkanes or halogenated C 3-5 Olefins.

26. The composition according to any one of claims 24-25, wherein C 3-5 Alkanes or halogenated C 3-5 The ratio of olefin to dimethyl ether ranges from about 6:1-0.5:1 w / w, about 5:1-1:2 w / w, about 4:1-1:1 w / w, about 4:2-1:1 w / w, 4:2-4:3 w / w, 4:3-1:1 w / w.

27. A composition according to any one of claims 1 to 6, The pharmaceutically acceptable lipid carrier comprises: 75-95% w / w white soft paraffin, 0.5-10% w / w liquid paraffin, and 0 to 10% w / w co-solvent; and The propellant is present in an amount equivalent to 30-80% w / w of the total composition.

28. The composition according to any one of claims 1 to 6, wherein The pharmaceutically acceptable lipid carrier comprises: 85-95% w / w white soft paraffin, 0.5-10% w / w liquid paraffin, and 0 to 10% w / w co-solvent; and The propellant is present in an amount equivalent to 40-70% w / w of the total composition.

29. The composition according to any one of claims 1 to 6, wherein The pharmaceutically acceptable lipid carrier comprises: 85-95% w / w white soft paraffin, 0.5-10% w / w liquid paraffin, and 0.5 to 10% w / w co-solvent; and The propellant is present in an amount equivalent to 55-65% w / w of the total composition.

30. The composition according to any one of claims 1 to 6, wherein The pharmaceutically acceptable lipid carrier comprises: 85-95% w / w white soft paraffin, 1-3% w / w liquid paraffin, and 3-7% w / w co-solvent; and The propellant is present in an amount equivalent to 55-65% w / w of the total composition.

31. The composition according to any one of claims 1 to 6, wherein The pharmaceutically acceptable lipid carrier comprises: 92% w / w white soft paraffin, 2% w / w liquid paraffin, and 5% w / w polyoxypropylene-11-stearyl ether; and The propellant is present in an amount equivalent to 58-62% w / w of the total composition.

32. A composition according to any one of claims 27 to 31 wherein the propellant comprises dimethyl ether.

33. A composition according to any one of claims 27 to 32, wherein the propellant comprises butane or a mixture of butane and propane.

34. A composition according to any one of claims 1 to 33 comprising an antioxidant.